Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4245328 | 0.79 | DRD2 (0.42) | TNKSMAP4K4 | |
| SCHEMBL3451122 | 0.74 | PIK3CD (0.37) | — | |
| SCHEMBL15882675 | 0.74 | SLC9A1 (0.33) | — | |
| SCHEMBL9946160 | 0.72 | TNKS (0.36) | TNKS | |
| SCHEMBL15882736 | 0.71 | MTOR (0.38) | — | |
| SCHEMBL9946158 | 0.71 | CYP2A6 (0.33) | — | |
| SCHEMBL15446196 | 0.69 | NOS3 (0.43) | — | |
| SCHEMBL12502375 | 0.69 | HCAR3 (0.40) | — | |
| SCHEMBL17863581 | 0.69 | MAPK1 (0.37) | — | |
| SCHEMBL12241915 | 0.68 | PIK3R1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20240174648-A1 | Small Molecule Compound | TECHNODERMA MEDICINES INC. (CN) | 2024-05-30 | — | — | US | disclosed |
| US-20220348593-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2022-11-03 | — | — | US | disclosed |
| CN-112004845-B | Resin composition, laminate, semiconductor wafer with resin composition layer, substrate, and semiconductor device | 三菱瓦斯化学株式会社 | 2022-05-31 | — | — | CN | disclosed |
| WO-2021078023-A1 | SMALL MOLECULE COMPOUND | 嘉兴特科罗生物科技有限公司 | 2021-04-29 | — | — | WO | disclosed |
| CN-112004845-A | Resin composition, laminate, semiconductor wafer with resin composition layer, substrate for mounting semiconductor with resin composition layer, and semiconductor device | 三菱瓦斯化学株式会社 | 2020-11-27 | — | — | CN | disclosed |
| CN-110627775-A | Small molecule compound | 嘉兴特科罗生物科技有限公司 | 2019-12-31 | — | — | CN | disclosed |
| US-20190330235-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2019-10-31 | — | — | US | disclosed |
| US-20170233407-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2017-08-17 | — | — | US | disclosed |
| US-9546182-B2 | Tricyclic PI3K inhibitor compounds and methods of use | GENENTECH, INC. | 2017-01-17 | — | — | US | disclosed |
| EP-3053925-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2016-08-10 | — | — | EP | disclosed |
| EP-2813506-B1 | Tricyclic PI3K inhibitor compounds and methods of use | HOFFMANN LA ROCHE (CH) | 2016-05-25 | — | — | EP | disclosed |
| US-20150079081-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| EP-2813506-A1 | Tricyclic PI3K inhibitor compounds and methods of use | F. Hoffmann-La Roche AG (CH) | 2014-12-17 | — | — | EP | disclosed |
| EP-2651951-B1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2014-11-19 | — | — | EP | disclosed |
| US-8883799-B2 | Tricyclic PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2651951-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-20120171199-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | NOVOGEN LIMITED (AU) | 2012-07-05 | — | — | US | disclosed |
| WO-2012082997-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA-ROCHE AG (CH) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330235-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | PI4KB, PI4KA, PIK3CA | TNKS 204/4885MAP4K4 82/4885 |
| US-20120171199-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, MTOR | TNKS 426/4885MAP4K4 145/4885 |
| US-20170233407-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | PI4KB, PI4KA, PIK3CA | TNKS 204/4885MAP4K4 82/4885 |
| US-20220348593-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, MTOR | TNKS 426/4885MAP4K4 145/4885 |
| US-20240174648-A1 | Small Molecule Compound | JAK1, JAK2, TYK2 | TNKS 536/4885MAP4K4 211/4885 |
| US-20150079081-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | PI4KB, PI4KA, PIK3CA | TNKS 204/4885MAP4K4 82/4885 |
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3C2B, PIK3C2A, PIK3R1 | TNKS 1272/4885MAP4K4 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.